[Discrimination between the effects of hypolipidemic and antiatherogenic drugs: probucol pharmacokinetics (review of the literature)].
Titov
V N
VN
Zaĭtseva
T M
TM
D000800:Angioplasty, Balloon; D015906:Angioplasty, Balloon, Coronary; D000818:Animals; D000924:Anticholesteremic Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001161:Arteriosclerosis / Q000097:blood / Q000378:metabolism / Q000517:prevention & control*; D002478:Cells, Cultured; D002784:Cholesterol / Q000097:blood / Q000378:metabolism; D003327:Coronary Disease / Q000517:prevention & control / Q000628:therapy; D005089:Exocytosis; D005228:Fatty Acids, Essential / Q000378:metabolism; D005347:Fibroblasts / Q000378:metabolism; D022781:Hepatocytes / Q000378:metabolism; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy*; D006951:Hyperlipoproteinemias / Q000097:blood / Q000188:drug therapy; D008075:Lipoproteins, HDL / Q000097:blood / Q000378:metabolism; D008077:Lipoproteins, LDL / Q000097:blood / Q000378:metabolism; D051379:Mice; D008822:Mice, Transgenic; D009131:Muscle, Smooth, Vascular / Q000166:cytology / Q000378:metabolism; D011341:Probucol / Q000737:chemistry / Q000493:pharmacokinetics* / Q000627:therapeutic use; D011817:Rabbits; D012008:Recurrence; D013997:Time Factors
D000924:Anticholesteremic Agents; D005228:Fatty Acids, Essential; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D002784:Cholesterol; D011341:Probucol